Wedbush Reiterates Outperform on Travere Therapeutics, Maintains $55 Price Target
Travere Therapeutics, Inc.
Travere Therapeutics, Inc. TVTX | 0.00 |
Wedbush analyst Laura Chico reiterates Travere Therapeutics (NASDAQ:
TVTX) with a Outperform and maintains $55 price target.
